Pain Management for Ambulatory Surgery: What Is New?

Hagen, Kathryn S.; Iohom, Gabriella

doi:10.1007/s40140-014-0079-0

Cited by 2 publications

(1 citation statement)

References 91 publications

(67 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Postoperative pain guidelines recommend multimodal analgesia [ 8 , 14 ]. There is a need for novel, multimodal, opioid-sparing analgesia—incorporating an anti-inflammatory—for the management of ambulatory postoperative pain [ 4 , 8 , 9 , 13 , 15 ].…”

Section: Introductionmentioning

confidence: 99%

Co-crystal of Tramadol-Celecoxib Versus Tramadol or Placebo for Acute Moderate-to-Severe Pain After Oral Surgery: Randomized, Double-Blind, Phase 3 Trial (STARDOM1)

Langford,

Pogatzki-Zahn,

Morte

et al. 2024

Adv Ther

View full text Add to dashboard Cite

Introduction Co-crystal of tramadol-celecoxib (CTC) is the first analgesic co-crystal for acute pain. This completed phase 3 multicenter, double-blind trial assessed the efficacy and safety/tolerability of CTC in comparison with that of tramadol in the setting of moderate-to-severe pain up to 72 h after elective third molar extraction requiring bone removal. Methods Adults ( n = 726) were assigned randomly to five groups (2:2:2:2:1): orally administered twice-daily CTC 100 mg (44 mg rac -tramadol hydrochloride/56 mg celecoxib; n = 164), 150 mg (66/84 mg; n = 160) or 200 mg (88/112 mg; n = 160); tramadol 100 mg four times daily ( n = 159); or placebo four times daily ( n = 83). Participants in CTC groups also received twice-daily placebo. The full analysis set included all participants who underwent randomization. The primary endpoint was the sum of pain intensity differences over 0 to 4 h (SPID 0–4 ; visual analog scale). Key secondary endpoints included 4-h 50% responder and rescue medication use rates. Safety endpoints included adverse events (AEs), laboratory measures, and Opioid-Related Symptom Distress Scale (OR-SDS) score. Results All CTC doses were superior to placebo ( P < 0.001) for primary and key secondary endpoints. All were superior to tramadol for SPID 0–4 (analysis of covariance least squares mean differences [95% confidence interval]: − 37.1 [− 56.5, − 17.6], − 40.2 [− 59.7, − 20.6], and − 41.7 [− 61.2, − 22.2] for 100, 150, and 200 mg CTC, respectively; P < 0.001) and 4-h 50% responder rate. Four-hour 50% responder rates were 32.9% (CTC 100 mg), 33.8% (CTC 150 mg), 40.6% (CTC 200 mg), 20.1% (tramadol), and 7.2% (placebo). Rescue medication use was lower in the 100-mg ( P = 0.013) and 200-mg ( P = 0.003) CTC groups versus tramadol group. AE incidence and OR-SDS scores were highest for tramadol alone. Conclusions CTC demonstrated superior pain relief compared with tramadol or placebo, as well as an improved benefit/risk profile versus tramadol. Trial registration ClinicalTrials.gov identifier, NCT02982161; EudraCT number, 2016-000592-24. Supplementary Information The online version contains supplementary material available at 10.1007/s12325-023-02744-2.

show abstract